Erratum: Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection (Open Forum Infect Diss (2016)3:2(ofw105) DOI: 10.1093/ofid/ofw105);Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection

Open Forum Infectious Diseases

Volumn 3, Issue 2, 2016, Pages

  Martinello, Marianne ^a,b   Dore, Gregory J ^a,b   Skurowski, Jasmine ^a   Bopage, Rohan I ^c,d   Finlayson, Robert ^e   Baker, David ^f   Bloch, Mark ^g   Matthews, Gail V ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c The Albion Centre   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Taylor Square Private Clinic ^*  (Australia)

^f East Sydney Doctors Darlinghurst   (Australia)

^g Holdsworth House Medical Practice   (Australia)

Author keywords

Antiretroviral therapy; Direct acting antiviral therapy; Drug drug interactions; Hepatitis C; HIV

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DACLATASVIR; DARUNAVIR PLUS RITONAVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELBASVIR PLUS GRAZOPREVIR; ELVITEGRAVIR PLUS COBICISTAT; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LEDIPASVIR PLUS SOFOSBUVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; MIXED INFECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH; TRANSIENT ELASTOGRAPHY; VIRUS LOAD;

EID: 84995646154     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofy033     Document Type: Erratum

References (39)

1. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61:S45-57.
2. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013, 2013. Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf. Accessed 13 March 2015.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.
4. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; pii:S1473-3099(15)00485-5.
5. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012; 57:743-51.
6. Branch AD, Van Natta ML, Vachon ML, et al. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis 2012; 55:137-44.
7. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41:779-89.
8. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117-71.
9. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49:22-31.
10. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 55:728-36.
11. Rodriguez-Torres M. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. Curr Opin Infect Dis 2013; 26:50-7.
12. Montes M, Nelson M, Girard PM, et al. Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis. J Int AIDS Soc 2014; 17:19626.
13. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:705-13.
14. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:714-25.
15. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis c in patients co-infected with hiv-1: a randomized trial. JAMA 2015; 313:1223-31.
16. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV coinfection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2:e319-27.
17. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, openlabel, non-randomised, phase 3 study. Lancet 2015; 385:1098-106.
18. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". Clin Infect Dis 2015; 60:1829-36.
19. Honer Zu Siederdissen C, Maasoumy B, Marra F, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis 2016; 62:561-7.
20. Poizot-Martin I, Naqvi A, Obry-Roguet V, et al. Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patients. PLoS One 2015; 10:e0141164.
21. Cope R, Pickering A, Glowa T, et al. Majority of HIV/HCV patients need to switch antiretroviral therapy to accommodate direct acting antivirals. AIDS Patient Care STDS 2015; 29:379-83.
22. Vivancos-Gallego MJ, Moreno A, Perez-Elias MJ, et al. Real-life renal safety of "boosted TDF" in HIV/HCV-patients on SOF/LDV. In: Conference on Retroviruses and Opportunistic Infections (Abstract 452). Boston, MA. February 22-25, 2016.
23. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54.
24. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-9.
25. Harvoni [full prescribing information]. Gilead Sciences Inc; Foster City, CA; 2015.
26. Viekira Pak [prescribing information]. AbbVie Inc; North Chicago, IL; 2015.
27. Zepatier [prescribing information]. Merck & Co. Inc., 2016. Available at: https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed 2 February 2016.
28. Olysio [prescribing information]. Janssen Therapeutics; Titusville, NJ; 2015.
29. Sovaldi [prescribing information]. Gilead Sciences Inc; Foster City, CA; 2015.
30. Daklinza [prescribing information]. Bristol-Myers Squibb Company. Princeton, NJ; 2015.
31. Mogalian E, Stamm L, Osinusi A, et al. Drug interaction studies between sofosbuvir/velpatasvir and boosted HIVARV regimens. In: Conference on Retroviruses and Opportunistic Infections (Abstract 100). Boston, MA. February 22-25, 2016.
32. Wyles D, Brau N, Kottilil S, et al. Sofosbuvir/Velpatasvir for 12 Weeks in Patients CoinfectedWith HCV and HIV-1: The ASTRAL-5 Study. The International Liver Congress. Barcelona, Spain. April 13-17, 2016.
33. Mogalian E, Stamm LM, Osinusi A, et al. Drug-drug interaction studies between HCV antivirals sofosbuvir and GS-5816 and HIV antiretrovirals. The Liver Meeting. San Francisco, CA. November 13-17, 2015.
34. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236.
35. AASLD/IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed 11 August 2015.
36. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2015. Available at: http://aidsinfo.nih.gov/guidelines. Accessed 10 November 2015.
37. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232-9.
38. Wells JT, Landaverde C, Gutierrez J, Lawitz E. Management of patients with hepatitis C virus resistance-associated variants to NS5A inhibitors: where are we now? Clin Liver Dis 2015; 6:82-5.
39. Khatri A, Dutta S, Wang H, et al. Evaluation of drug-drug interactions between hepatitis C antiviral agents ombitasvir, paritaprevir/ritonavir, and dasabuvir and HIV-1 protease inhibitors. Clin Infect Dis 2016; 62:972-9.